What is Laboratory Corporation of America Holdings (LH) DCF Fair Value and Intrinsic Value in 2026?

Laboratory Corporation of America Holdings (LH) intrinsic value is calculated using conservative multi-stage Discounted Cash Flow (DCF) models, 5-year free cash flow trajectories, Graham Numbers, and owner earnings multiples. LocalAlpha tracks real-time margin of safety against live market prices.

What is Laboratory Corporation of America Holdings's historical Return on Invested Capital (ROIC) and Moat Rating?

Laboratory Corporation of America Holdings operates in the Healthcare sector (Diagnostics & Research) with an economic moat rating of NARROW. LocalAlpha tracks 5-year audited quarterly ROIC, operating margin stability, and balance sheet solvency ratios.

What is Laboratory Corporation of America Holdings's financial health rating and Piotroski F-Score?

Laboratory Corporation of America Holdings's balance sheet quality is evaluated using the 9-point Piotroski F-Score, Altman Z-Score solvency model, debt-to-equity ratio, and quick/current liquidity coverage to guard against financial distress.

How does LocalAlpha monitor Laboratory Corporation of America Holdings (LH) for quarterly SEC filing thesis breaks?

LocalAlpha audits Laboratory Corporation of America Holdings's 10-K, 10-Q, and 8-K regulatory filings on SEC EDGAR within 15 minutes of release. If reported metrics breach an investor's custom ROIC floor, operating margin boundary, or qualitative risk criteria, an autonomous breach audit is dispatched immediately.

StocksLH

LH

Labcorp Holdings Inc.Healthcare / Diagnostics & ResearchINTACT

Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.

Share Price

$306.36

52W: $244.52 - $341.8

DCF Fair Value

$133.25

-129.9% Premium

Thesis Hub

P/E (TTM)

25.3x

ROIC

9.1%

Operating Margin

12.2%

FCF Yield

3.6%

Debt / Equity

0.79x

Piotroski Score

7/9

Altman Z-Score

3.89

Market Cap

$24.8B

Price vs. Intrinsic Value Corridor

Overvalued vs DCF ($133.25)

Historical market price overlaid against conservative DCF Fair Value & Benjamin Graham Margin of Safety bands.

Period Return (1Y)

—()

Period Range

$— - $—

DCF Fair Value

$133.25

MOS Buy Target (-25%)

$99.94

Valuation Overlays: DCF Fair Value ($133.25) 25% MOS Buy Target ($99.94) Revised Graham ($195.05) Graham Number ($170.12)

2-Stage Discounted Cash Flow (DCF) Workbench

Conservative intrinsic value model based on owner cash generation over a 10-year investment horizon. Opens with LocalAlpha's baseline assumptions (matching the fair value shown above) — adjust any input to stress-test.

Current Market Price

$306.36

DCF Fair Value

$133.49

-129.5% Premium

Starting Free Cash Flow ($M)$892M

$100M$892M (Reported)$50,000M

Stage 1 Growth (Years 1-5)6.1%

-5%10% (Target)35%

Stage 2 Growth (Years 6-10)4.5%

0%5%20%

Discount Rate (WACC / Hurdle)9.0%

6%9% (Standard)15% (High Risk)

Terminal Perpetual Growth2.5%

1% (GDP Floor)2.5% (Inflation)4.0%

Net Debt ($M)$6,700M

-$100B CashBalance Sheet+$150B Debt

10-Yr PV of Cash Flows

$7.6B

PV of Terminal Value

$10.0B

Implied Enterprise Value

$17.5B

Implied Equity Value

$10.8B

Year	Yr 1	Yr 2	Yr 3	Yr 4	Yr 5	Yr 6	Yr 7	Yr 8	Yr 9	Yr 10
Projected FCF ($M)	$946	$1,004	$1,065	$1,130	$1,199	$1,253	$1,310	$1,369	$1,430	$1,495
Present Value (PV)	$868	$845	$823	$801	$779	$747	$716	$687	$659	$631

Benjamin Graham & Buffett Value Models

Classical deep value metrics based on asset backing, normalized earnings power, and owner cash yield.

Graham Number-80.1% Premium

$170.12

Calculated as √(22.5 × EPS × BVPS). The maximum theoretical price a defensive investor should pay based purely on asset book value and current earnings.

EPS: $12.09BVPS: $106.39

Revised Graham Formula-57.1% Premium

$195.05

Formula: V = (EPS × (8.5 + 2g) × 4.4) / Y where g is the conservative 7-10 yr growth rate and Y is AAA Bond Yield.

Growth Rate (g%)

Bond Yield (Y%)

Buffett Owner Earnings3.4% Yield

$10.46 / share

True distributable cash flow: Net Income + D&A - Maintenance CapEx. Reflects the cash Buffett would extract without hurting unit volume.

Total: $0.8BYield: 3.4%

Reverse DCF: Market Growth Expectation

FAIR BARRIER

10.0% CAGR (Next 10 Yrs)

At the current price of $306.36, the market is assuming the business will compound Free Cash Flow at 10.0% per year for the next decade with a 9% hurdle rate.

Value Investor Verdict

ℹ Fair expectations: Requires steady execution.

Autonomous Thesis Underwriting

Surveil LH with Mathematical Margin of Safety Rules

Set non-negotiable floor rules for Labcorp Holdings Inc.. If a newly filed quarterly 10-Q breaks your ROIC floor, operating margin boundary, or balance sheet leverage rules, receive an autonomous breach audit within 15 minutes.

Buffett Quality

ROIC > 15% • Margin > 15% • D/E < 0.5x

Margin Floor Guard

Current Margin 12.2% • Floor > 10%

Solvency Guard

Altman-Z > 2.6 • Current Ratio > 1.5x

Track LH & Set Alerts Browse S&P 500 Coverage

Frequently Asked Questions: Labcorp Holdings Inc. (LH) Intrinsic Valuation

Audited fundamentals, DCF intrinsic value sensitivity, and thesis break detection parameters for Labcorp Holdings Inc..

Based on institutional multi-stage Discounted Cash Flow (DCF) modeling on audited SEC cash flows, Labcorp Holdings Inc. has an estimated DCF intrinsic fair value of $133.25 per share compared to its current market price of $306.36. This represents an estimated 129.9% premium over fair value. Additionally, its classic Benjamin Graham Number stands at $170.12.